Sermorelin Compounding Pharmacy: How to Choose a Peptide Compounder

What Sermorelin Is and Why It Must Be Compounded

Sermorelin acetate is a 29-amino-acid synthetic fragment of endogenous growth hormone-releasing hormone (GHRH 1-29). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone secretion. Unlike recombinant human growth hormone, sermorelin acts upstream, so the pituitary retains normal feedback control and IGF-1 does not spike artificially.

The FDA approved Geref Diagnostic (sermorelin acetate) for pediatric GH deficiency testing in 1990, but the brand was voluntarily withdrawn from the U.S. Market in 2008. No commercially manufactured sermorelin product exists today. Every vial a patient receives is, by definition, a compounded preparation made by a licensed pharmacy under a physician's prescription.

That legal reality has two consequences. First, the quality of the product depends entirely on the pharmacy's manufacturing controls, not on an FDA-approved manufacturing site. Second, both federal and state law impose specific requirements on those pharmacies, which gives buyers a concrete checklist to verify before accepting any prescription fill.

The FDA's Drug Shortage and Compounding page clarifies that compounded drugs are not FDA-approved, meaning the agency has not independently verified their safety, efficacy, or quality. That gap makes pharmacy-level quality controls the patient's primary protection.

The Regulatory Framework: What the Law Actually Requires

Federal Law: 503A vs. 503B

Two pathways govern compounded sermorelin in the United States. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional patient-specific compounding pharmacies. These pharmacies must compound only in response to a valid prescription for an identified patient, comply with USP standards, and operate under a state board of pharmacy license. They are not subject to FDA's current Good Manufacturing Practice (cGMP) regulations, but they must follow USP <797> standards for sterile preparations.

Section 503B covers outsourcing facilities, which may produce larger batches without patient-specific prescriptions. The FDA inspects 503B facilities under cGMP and publishes inspection findings. A list of registered 503B outsourcing facilities is maintained on the FDA's outsourcing facility database. If your pharmacy claims 503B status, verify it appears on that list.

State Board Licensing

Every 503A pharmacy must hold an active license in the state where it dispenses. Pharmacies shipping across state lines require non-resident pharmacy licenses in recipient states. The National Association of Boards of Pharmacy (NABP) maintains a "Not Recommended" list of online pharmacies operating outside of legal standards. Checking that list takes under two minutes and screens out the most obvious bad actors.

The Drug Supply Chain Security Act (DSCSA)

The DSCSA, enacted in 2013, requires pharmacies to track and trace drug products through the supply chain. For compounders, this translates to maintaining records of active pharmaceutical ingredient (API) sourcing. Ask your pharmacy directly: where does their sermorelin API originate? A compliant pharmacy should confirm it uses a DEA-registered, FDA-inspected API supplier, not a raw chemical vendor with no pharmaceutical-grade certification.

USP Standards That Actually Protect Patients

USP <797>: Sterile Compounding

USP <797> sets the minimum standards for sterile preparations, including injectable peptides like sermorelin. The 2023 revision, which became official on November 1, 2023, tightened requirements around beyond-use dating, environmental monitoring, and personnel training. The revised chapter is described in detail by the FDA.

Under USP <797>, a compliant pharmacy must maintain ISO Class 5 primary engineering controls (laminar flow hoods or biological safety cabinets), conduct surface and air sampling for microbial contamination, test finished batches for sterility, and assign beyond-use dates based on sterility testing results rather than convenience.

A pharmacy that cannot produce an environmental monitoring log or explain its ISO classification has almost certainly not invested in the physical infrastructure those standards require.

USP <71>: Sterility Testing

USP <71> governs direct sterility testing of finished products. For sermorelin, which is administered by subcutaneous injection, a sterility failure carries real clinical risk: bacteremia, abscess, or systemic infection. Published case series and FDA warning letters document infections tied to non-sterile compounded injectables. The FDA's database of warning letters to compounding pharmacies shows repeated citations for sterility failures, with some facilities receiving multiple letters over consecutive years.

USP <85>: Bacterial Endotoxin Testing

Bacterial endotoxins (pyrogens from gram-negative bacteria) cause fever, rigors, and septic shock even in a technically sterile preparation. USP <85> specifies the Limulus Amebocyte Lysate (LAL) test for endotoxin quantification. For injectable peptides, the general limit is 5 EU/kg/hour based on the patient's weight and the injection volume. For a typical sermorelin dose of 300 mcg in 0.3 mL, a compliant pharmacy should target endotoxin below 14 EU/dose. Ask for the endotoxin value on the certificate of analysis (CoA), not just a pass/fail notation.

HPLC Purity: The Single Most Informative Quality Number

High-performance liquid chromatography (HPLC) separates the peptide from synthesis byproducts, degradation fragments, and related impurities. The HPLC purity percentage on a CoA tells you what fraction of the material in the vial is actually sermorelin versus everything else.

What Purity Threshold to Require

For a prescription injectable peptide, require HPLC purity of 98% or higher. Research-grade peptides sold to laboratories commonly show 95% purity, which sounds close but means 50 mg of impurities per gram of peptide, some of which may be pharmacologically active fragments. A peer-reviewed analysis of commercially purchased peptides found that many samples labeled as research-grade fell below stated purity when independently tested. Research published in JAMA in 2018 on compounded drug quality documented that a substantial proportion of compounded preparations failed potency specifications, reinforcing the need for pharmacy-specific CoAs rather than reliance on category-level trust.

Mass Spectrometry Confirmation

HPLC alone confirms purity but not molecular identity. A serious compounder should also provide mass spectrometry (MS) data confirming the molecular weight of the finished peptide matches sermorelin's expected mass of 3357.9 Da. If a pharmacy only provides HPLC and not MS, that is not automatically disqualifying, but MS data should be available for at least the API batch used.

Reading a Certificate of Analysis

The CoA should display the batch number, compounding date, beyond-use date, HPLC purity percentage, endotoxin result in EU/mL or EU/dose, sterility result, pH, and the testing laboratory's name. Third-party testing by an independent ISO 17025-accredited laboratory is a higher bar than in-house testing. Ask whether the listed laboratory is actually independent or a sister company.

PCAB Accreditation: What It Means and What It Misses

The Pharmacy Compounding Accreditation Board (PCAB), administered by URAC, audits compounding pharmacies against a set of quality standards covering facility design, standard operating procedures, personnel qualifications, and quality management systems. PCAB accreditation is voluntary, not mandatory. Roughly 250 to 300 pharmacies hold PCAB accreditation at any given time, representing a small fraction of the estimated 7,500 compounding pharmacies in the United States.

Accreditation signals a baseline commitment to quality. The on-site audit cycle reviews real batch records, environmental monitoring data, and training logs, things that are difficult to fabricate for an inspector. However, PCAB does not independently test the finished product in every batch. Accreditation is a process audit, not a product guarantee.

A non-PCAB pharmacy that provides third-party CoAs for every batch, maintains state board inspection records, and voluntarily shares environmental monitoring data may be safer than a PCAB-accredited pharmacy that treats accreditation as a marketing badge and lets documentation slip. Use accreditation as a positive signal, not as a substitute for reviewing the actual CoA.

The Accreditation Commission for Health Care (ACHC) also offers pharmacy compounding accreditation, and some high-volume 503B facilities carry both ACHC and state-specific certifications. Either credential is worth confirming directly on the accreditor's public directory.

Is Sermorelin Legal? A Plain-Language Answer

Sermorelin is legal in the United States when prescribed by a licensed physician and dispensed by a licensed compounding pharmacy. It is not a controlled substance. It is not on the FDA's Category 1 or Category 2 lists of bulk drug substances that have been prohibited for compounding. Under current FDA policy, sermorelin may be compounded by 503A pharmacies under patient-specific prescriptions.

One important nuance: the FDA does periodically revisit which substances are appropriate for compounding. The FDA's current bulk drug substances list should be checked by the prescribing physician at the time of prescribing, because the regulatory environment can shift.

Sermorelin is also distinct from growth hormone itself, which is a Schedule III-adjacent substance with tighter prescribing restrictions. Sermorelin is not scheduled, which means a physician may prescribe it for any medically appropriate indication without the DEA registration requirements that govern actual GH prescribing.

The research-grade peptide market occupies a legally grey zone. Vendors selling sermorelin labeled "for research purposes only, not for human use" are technically selling an unregulated chemical, not a pharmaceutical. These products carry no sterility, endotoxin, or purity guarantees enforceable under pharmacy law. A 2022 JAMA Network Open study examining self-administered peptides obtained outside clinical channels found significant purity and contamination concerns, which underscores why physician oversight and pharmacy-grade sourcing matter clinically.

Practical Red Flags and Green Flags

Red Flags: Walk Away Immediately

• The pharmacy sells without a prescription.
• No CoA is available, or the pharmacy refuses to share one.
• The CoA lists only pass/fail with no numerical HPLC value.
• The API supplier is not identified, or the supplier is based in China with no FDA inspection history.
• The pharmacy has an active FDA warning letter or NABP "Not Recommended" listing.
• Pricing is dramatically below market (sermorelin at legitimate pharmacies typically runs $150 to $350 per month depending on dose).
• The website markets sermorelin directly to consumers with no mention of prescriptions.

Green Flags: Evidence of Legitimate Operation

• Active state board license, verifiable through the state's public license lookup.
• PCAB or ACHC accreditation listed and confirmable on the accreditor's directory.
• Third-party CoA available for the specific batch, with HPLC purity ≥98% and a named independent laboratory.
• Endotoxin value reported in numeric EU/dose, not just "pass."
• API sourced from an FDA-inspected, registered domestic supplier.
• A licensed pharmacist available by phone to discuss compounding procedures.
• The prescribing process involves a physician evaluation, not a checkbox questionnaire.

Clinical Evidence Supporting Sermorelin Use

Sermorelin's efficacy in stimulating GH secretion is well-established at the pituitary pharmacology level. A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that GHRH administration significantly elevated IGF-1 levels in GH-deficient adults, consistent with the upstream mechanism sermorelin employs. A separate NIH-indexed review of GHRH analogues confirmed pulsatile GH release with preserved feedback inhibition, distinguishing the physiological profile from exogenous GH administration.

A 6-month placebo-controlled trial of GHRH peptides in older adults with relative GH deficiency, indexed in PubMed, showed increases in lean mass and reductions in fat mass compared to placebo, with the effect size correlating with degree of GH secretory restoration. These findings support the rationale for sermorelin in adults with documented GH secretory decline, though the prescribing physician must assess indication on an individual basis.

The Endocrine Society's clinical practice guideline on adult GH deficiency states: "Diagnosis of adult GH deficiency requires biochemical confirmation using a validated stimulation test." Sermorelin is sometimes used as part of that diagnostic evaluation, in addition to its therapeutic applications, which reinforces the point that prescribing must be tied to documented clinical assessment rather than symptom checklists alone.

How to Verify a Pharmacy Before Filling Your Prescription

The verification process takes about 15 to 20 minutes and can be done entirely online before your prescription is sent anywhere.

Step 1: Check State License Status

Search the state board of pharmacy's public license lookup for the pharmacy's name and license number. Confirm the license is active and has no disciplinary actions. If the pharmacy ships to your state, also confirm they hold a non-resident pharmacy license in your state.

Step 2: Check NABP and FDA Databases

Search the NABP's website for the pharmacy name. Cross-check the FDA warning letters database using the pharmacy's name and city. A single warning letter from years ago that has been resolved is different from an active enforcement action.

Step 3: Request the CoA Before Paying

A legitimate pharmacy will provide a CoA for the specific lot number your prescription will be filled from, or for the most recent batch of the same formulation. If the pharmacy stalls, provides a generic document without a lot number, or claims the CoA is proprietary, that is a hard stop.

Step 4: Confirm the Testing Laboratory

Look up the laboratory listed on the CoA. Confirm it holds ISO 17025 accreditation for the relevant test methods. The ILAC MRA Partner Database can help verify accreditation status for U.S. Laboratories.

Step 5: Speak With a Pharmacist

Call the pharmacy and ask to speak with the compounding pharmacist, not a customer service representative. Ask: What ISO classification is your cleanroom? How often do you conduct surface sampling? What is your typical endotoxin result for sermorelin batches? A pharmacist who can answer these fluently operates in a different category from one who deflects.

Dosing Context and Prescription Requirements

A valid sermorelin prescription should specify the concentration (commonly 9 mg/3 mL or 15 mg/3 mL vials), the dose in micrograms, the injection route (subcutaneous), the frequency (typically nightly, to align with the physiologic GH pulse), and the beyond-use date. Doses in published trials and clinical practice range from 200 mcg to 500 mcg at bedtime. Doses above 500 mcg nightly are outside typical usage and warrant additional clinical justification.

The prescription must originate from a physician who has performed or reviewed relevant baseline labs, typically serum IGF-1 and potentially an insulin tolerance test or GHRH-arginine stimulation test per Endocrine Society guidelines. Telehealth platforms that prescribe sermorelin after a brief symptom questionnaire without lab review are not meeting the diagnostic standard the guideline describes, and that shortcut affects both safety and the legitimacy of the prescription itself.